Pricing Log in Create free account

Carisma Therapeutics Inc. (CARM) vs Oragenics, Inc. (OGEN)

Carisma Therapeutics Inc. and Oragenics, Inc. are both Biotechnology companies. Carisma Therapeutics Inc. and Oragenics, Inc. are of similar size ($1.6M and $1.5M). Carisma Therapeutics Inc. grew revenue faster over the last twelve months: 170.5% against −75.1%. Carisma Therapeutics Inc. has the higher net margin (14.4% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Carisma Therapeutics Inc. leads on 11 and Oragenics, Inc. on 3.

Valuation

Metric CARM OGEN Biotechnology median
P/E n/m n/m 10.60
P/S n/m 12.53 9.40
P/B n/m 0.42 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales (0.05) 0.69 9.02
Earnings yield 0.00% (982.63%) (32.88%)
Free cash flow yield 0.00% (656.98%) (23.13%)

Profitability

Metric CARM OGEN Biotechnology median
Gross margin 100.00% 19.89% 68.51%
Operating margin 19.36% 0.00% 0.00%
Net margin 14.36% 0.00% 0.00%
Free cash flow margin (38.79%) 0.00% 0.00%
Return on equity (134.11%) (1,307.07%) (51.96%)
Return on assets 33.09% (264.23%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CARM OGEN Biotechnology median
Revenue growth (TTM) 170.48% (75.08%) 6.76%
EPS growth (last fiscal year) 43.68% 90.51% 29.88%
Revenue growth, 5-year CAGR 115.24% (50.98%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CARM OGEN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.86 3.01 4.97
Net debt to EBITDA 0.30 0.98 1.01

Dividend

Metric CARM OGEN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CARM OGEN Biotechnology median
Market cap 1.52m 1.58m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack